Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Melanoma and Skin Cancer Treatment

Melanoma and Skin Cancer Treatment at Sheba

Offering cutting-edge medicine with a personal touch, Sheba tailored each patient a holistic treatment plan by leveraging the expertise of an interdisciplinary team of dermatologists, medical oncologists, pathologists, surgeons, and researchers. In this manner, we ensure our patients the best possible treatment outcomes.

The Ella Lemelbaum Institute for Immuno-Oncology is dedicated to world-class melanoma treatment and continuous research into this widespread disease. Our top-tier staff, including experienced clinicians, researchers, and nurses, strives to provide patients and their families with total integrative care. To that end, the Ella Institute works with some of the leading melanoma treatment centers around the world, including the U.S. National Institutes of Health (NIH).

We are proud to provide the absolute latest in melanoma treatment, including advanced immunotherapy techniques, and offer patients the opportunity to participate in ongoing clinical studies.

Melanoma Treatment


Skin Cancer

The most prevalent type of cancer worldwide, skin cancer is caused by unrepaired DNA damage to skin cells, which triggers mutations (genetic defects). These mutations spark abnormal skin cells to multiply rapidly, forming malignant tumors that can spread to other parts of the body. Skin cell damage is largely caused by excessive exposure to ultraviolet (UV) rays, and 90 percent of non-melanoma skin cancers are linked to exposure to UV radiation.
The most common form of skin cancer is basal cell carcinoma, followed by squamous cell carcinoma and melanoma.


Melanoma accounts for less than one percent of skin cancers, yet it is one of the most aggressive, responsible for the majority of skin cancer mortalities (about 80%). It develops in melanocytes, the cells responsible for pigment production in the skin, and can form in any area of skin. Approximately 1,800 people are diagnosed with melanoma in Israel every year.
When detected early and while it is still localized, melanoma can almost always be successfully treated.



The four most common types of melanoma are:

| 1

Superficial spreading melanoma. This type accounts for approximately 70% of melanomas, usually developing from an existing mole.

| 2

Lentigo maligna melanoma. This type of melanoma usually manifests in the elderly. It most commonly begins on the face, ears, arms, and other sun-exposed areas.

| 3

Nodular melanoma. About 15% of melanomas fall into this category. It often appears rapidly as a bump on the skin, which in most cases is black, but may also be pink or red.

| 4

Acral lentiginous melanoma. This type of melanoma develops on the palms of the hands, soles of the feet, or under the nail bed. People with darker skin may be more susceptible to it. Acral lentiginous melanoma is not related to sun exposure.


| Stage 0

In stage 0 melanoma, the malignant tumor is still confined to the upper layer of the skin. The melanoma is in situ (which means “in place” in Latin), and there is no evidence that the cancer has spread to the lymph nodes or distant organs (metastasis).

| Stage 1

In stage 1 melanoma, there are cancer cells in both the epidermis and dermis, and there is no evidence that cancer has spread to lymph nodes or distant sites (metastasis).

| Stage 2

Stage 2 melanoma is defined by tumor thickness and ulceration. There are cancer cells in both the epidermis and dermis, but there is no evidence that the cancer has spread to the lymph nodes or distant organs (metastasis).

| Stage 3

Stage 3 melanoma is defined by the level of lymph node involvement and ulceration. In stage 3 melanoma, cancer has spread to one or more regional lymph nodes or developed a deposit of melanoma in the skin or dermis along the lymphatic vessels before reaching a lymph node. This is called an in-transit or satellite metastasis. There must, however, be no evidence that the cancer has spread to distant organs (metastasis).

| Stage 4

In stage 4 melanoma, the cancer has spread beyond the original tumor site and regional lymph nodes to more distant areas of the body. The most common sites of metastasis are distant skin and lymph nodes, followed by the lungs, liver, brain, bone and/or intestines.

Risk Factors

The exact cause of melanoma remains unclear, but extended exposure to ultraviolet (UV) radiation puts you at greater risk.

Melanoma risk factors include:

  • Extended exposure to ultraviolet light from the sun or other sources. Anyone who spends considerable time in the sun is at greater risk of developing skin cancer, especially if the skin isn’t protected by sunscreen or clothing. Tanning, including exposure to tanning lamps and beds, also puts you at risk. A tan is your skin’s injury response to excessive UV radiation.
  • Advanced age. Melanoma can occur at any age, but is most prevalent in the sixth and seventh decades of life.
  • Family history of skin cancer. If one of your parents or a sibling has had skin cancer, you may be at increased risk of developing it as well.
  • Pale skin. Anyone, regardless of skin color, can get skin cancer. However, having less pigment (melanin) in your skin provides less protection from damaging UV radiation. If you have blond or red hair, light-colored eyes, and freckle or sunburn easily, you’re much more likely to develop skin cancer than a person with darker skin.
  • The presence of numerous moles. People with a large number of moles, or abnormal moles called dysplastic nevi, are at increased risk of developing skin cancer. These abnormal moles — which look irregular and are generally larger than normal moles — are more likely than others to become cancerous. If you have a history of abnormal moles, be sure to monitor them for changes regularly.
  • A history of severe sunburns. Having had one or more blistering sunburns as a child or teenager increases your risk of developing skin cancer as an adult. Sunburns in adulthood are also a risk factor.
  • Geographical location. People who live in warm, sunny climates are exposed to more sunlight compared to those who live in colder climates. Living at higher elevations, where the sunlight is strongest, also exposes you to more UV radiation.


Most skin cancers are preventable. To protect yourself, follow the tips below:

  • Avoiding the sun at its strongest helps you prevent sunburns and suntans that cause skin damage and increase your risk of developing skin cancer. Accumulated sun exposure over time can also cause skin cancer.
  • Apply sunscreen year-round. Sunscreen doesn’t filter out all harmful UV radiation, but can play a crucial role in an overall skin protection regimen.
  • Wear protective clothing. As sunscreen doesn’t provide complete protection from UV rays, it is recommended to cover your skin with dark, tightly woven clothing that protects your arms and legs, and a broad-brimmed hat, which provides more protection than a baseball cap or visor.
  • Don’t forget sunglasses. Look for those that block both types of UV radiation — UVA and UVB.
  • Avoid tanning beds. Lights used in tanning beds emit UV rays and can increase your risk of skin cancer.
  • Examine your skin often for new growth or changes in moles, freckles, bumps, and birthmarks, and report any changes to your doctor.


Some signs and symptoms of skin cancer include:

  • A change in the appearance of the skin, such as changes in a mole’s shape or color, new moles, and other blemishes
  • Scaly or bleeding skin areas
  • Skin sores that do not heal
  • Skin soreness

Melanoma Indicative Moles

When identifying moles with unusual characteristics, use the ABCDE principle:

| A

is for asymmetrical shape. Look for moles with irregular shapes, such as two very different-looking halves.

| B

is for irregular borders. Look for moles with irregular, notched, or scalloped borders — characteristics of melanomas.

| C

is for changes in color. Look for growths that have many colors or an uneven distribution of color.

| D

is for diameter. Look for new growth in a mole larger than 1/4 inch (about 6 millimeters).

| E

is for evolving. Look for changes over time, such as a mole that grows in size or changes color or shape. Moles may also evolve to develop new signs and symptoms, such as new itchiness or bleeding.


Melanoma is diagnosed using the following tests and procedures:

  • Physical exam. Your doctor will ask questions about your medical history and examine your skin to look for signs that may indicate melanoma.
  • Removing a tissue sample for testing (biopsy) to determine whether a suspicious skin lesion is a melanoma. The sample will then be sent to a lab for examination.



The main treatment for melanoma is surgical removal of the primary melanoma on the skin. Surgical procedures will vary depending on the thickness of the melanoma. Typically, doctors remove the tumor, the tissue found under the skin, and some surrounding healthy tissue, called a margin, to ensure that no cancer cells remain.

Targeted Therapy

Melanoma targeted therapies include:

  • BRAF inhibitors: Mutations in the BRAF gene cause melanoma cells to produce proteins that help cancer cells grow. About half of melanoma skin cancers have the BRAF mutation. BRAF inhibitors include vemurafenib, dabrafenib, and encorafenib.
  • MEK inhibitors: The MEK protein works with the BRAF gene. Medications targeting the MEK protein can treat melanomas with BRAF mutations. MEK inhibitors include trametinib, cobimetinib, and binimetinib.


  • Immune Checkpoint Inhibitors
  • Immune checkpoint inhibitors, specifically anti-CTLA4 and anti-PD-1 antibodies, have revolutionized the management of many cancers, particularly advanced melanoma, for which tumor regression and long-term durable cancer control is possible in nearly 50% of patients, compared with less than 10% historically.

  • Adoptive Cell Therapy
  • Adoptive cell transfer therapy, or ACT, includes several different types of immunotherapy. All of these approaches involve growing large numbers of immune cells in a lab and introducing them into the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while in other cases, cells are modified to make them recognize and kill the melanoma cells.

    One particularly promising ACT is tumor-infiltrating lymphocyte therapy (TIL): a procedure for patients with malignant metastatic melanoma with very encouraging results. The therapy involves removing T-cells found in the tumor itself, then multiplying and reintroducing them to the patient’s body. Sheba is a recognized global leader in TIL, which is offered in a limited number of healthcare institutions worldwide.

Open-chest surgery

Clinical Research

Continuous research is conducted at the Ella Institute, with over 10 studies currently ongoing. Eligible patients receive treatment under the strictest ethical and safety standards.

Sheba Medical Center is a leader in tumor-infiltrating lymphocytes (TIL) immunotherapy. TIL is a promising treatment for patients with malignant metastatic melanoma, or melanoma that has spread beyond the outermost layers of the skin. These patients often have weakened immune systems and receive transfers of immune cells, with very encouraging results having been seen in clinical research. Sheba Medical Center has improved the TIL protocol and hopes to make use of it in other types of cancer in the future.

Ongoing Clinical Research:

Stage IIB/ IIC -Adjuvant

  • Special considerations: 1 year treatment every 4W. BRAF test in Study Central Lab.
  • Inclusion/Exclusion criteria: 14W from Primary Melanoma biopsy. SLNB Negative and 12W from SLNB + BRAF.

Stage III operable disease Neo-Adjuvant

  • Special considerations: Screening 3-4w. Treatment 6w. Total 10w delay in surgery.
  • Inclusion/Exclusion criteria: Stage IIIB-D, macroscopic. No in-transit.

Immunotherapy naïve (failure on BRAF allowed)

  • Special considerations: No steroids at least 10 days (allowed prednisone 10mg).
  • Inclusion/Exclusion criteria: Measurable brain metastasis. Asymptomatic. Max 5 lesions. 10-30mm max diameter. Possible. prior SRS for max 3 lesions. Possible prior resection of max 2 lesions. Mucosal allowed. No mucosal, no uveal. No active brain mets (stable 4w).

PD-1 refractory

  • Special considerations: No steroids at least 10 days (allowed prednisone 10mg).
  • Inclusion/Exclusion criteria: Measurable brain mets. Asymptomatic. Max 5 lesions. 10-30mm max diameter. Possible prior. SRS for max 3 lesions. Possible prior resection of max 2 lesions. Mucosal allowed.

Our Staff

Ronnie Shapira
Dr. Ronnie Shapira
Director of the Ella Institute
Is one of Israel’s leading medical oncologists and is an Acting Director of the Ella Institute. Dr. Shapira received her MD from the Sackler School of Medicine at Tel Aviv University and completed her residency at Meir Medical Center.
Read More
Dr. Yochai Wolf
Principal Investigator
Serves as the Principal Investigator at Ella Lemelbaum institute for Immuno-oncology. His areas of expertise are cancer immunology and metabolism.

Request a consultation

Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.

We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.

Request a consultation and a Sheba Case Manager will contact you shortly: